Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4)

por Goldfarb, David S., Lieske, John C., Groothoff, Jaap, Schalk, Gesa, Russell, Kerry, Yu, Shuli, Vrhnjak, Blaz
Publicado 2023

Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4)

por Goldfarb, David S., Lieske, John C., Groothoff, Jaap, Schalk, Gesa, Russell, Kerry, Yu, Shuli, Vrhnjak, Blaz
Publicado 2023

Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs

por Cherney, David Z.I., Hadjadj, Samy, Lawson, Jack, Mosenzon, Ofri, Tuttle, Katherine, Vrhnjak, Blaz, Rasmussen, Søren, Bain, Stephen C.
Publicado 2022